Literature DB >> 11156242

Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.

M V Dhodapkar1, J W Young, P B Chapman, W I Cox, J F Fonteneau, S Amigorena, A N Houghton, R M Steinman, N Bhardwaj.   

Abstract

The functional characteristics of CD8+ T cells specific for melanoma antigens (MAs) have often been defined after in vitro culture using nonprofessional antigen-presenting cells. We have examined CD8+ T-cell immunity to MAs and a viral antigen (influenza) in uncultured T cells of healthy donors and melanoma patients using autologous, mature, monocyte-derived dendritic cells (DCs) pulsed with peptide antigens and viral vectors. Antigen-specific IFN-gamma-producing T cells reactive with HLA-A*0201-restricted peptides from four melanoma antigens (MelanA/MART-1, MAGE-3, tyrosinase, and gp100) were detected only at low frequencies (<30 per 2 x 10(5) peripheral blood mononuclear cells for each of the MAs) from HLA-A2.1-positive healthy donors (n = 12) and patients with stages III/IV melanoma (n = 8). Detection of MA-specific, but not influenza matrix peptide (Flu-MP)-specific, T cells required a high concentration (10 microg/ml) of the peptide in this assay. Furthermore, these T cells did not recognize endogenously processed antigen on tumor cell lines or cells infected with viral vectors capable of expressing MAs. The use of autologous, mature DCs led to a significant increase in the number of Flu-MP, but not MA-specific, T cells in 16-h ELISPOT assays for both melanoma patients and healthy donors. In 1-week cocultures with DCs pulsed with 10 microg/ml peptide, MelanA/MART-1-specific T cells did not readily proliferate or differentiate into lytic effectors, in contrast to strong influenza-specific lytic responses. Therefore, despite distinct memory responses to influenza antigens, melanoma patients and healthy controls have a paucity of MA-reactive memory T cells, failing to rapidly generate IFN-gamma-secreting lytic effectors in short-term assays, even when stimulated by DCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156242

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.

Authors:  Shuang-Jian Qiu; Lina Lu; Chunping Qiao; LiangFu Wang; Zhong Wang; Xiao Xiao; Shiguang Qian; John J Fung; Sheng-Long Ye; C Andrew Bonham
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-08       Impact factor: 4.553

Review 2.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

3.  A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.

Authors:  Elizabeth K Duperret; Shujing Liu; Megan Paik; Aspen Trautz; Regina Stoltz; Xiaoming Liu; Kan Ze; Alfredo Perales-Puchalt; Charles Reed; Jian Yan; Xiaowei Xu; David B Weiner
Journal:  Clin Cancer Res       Date:  2018-09-27       Impact factor: 12.531

Review 4.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

5.  A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

Authors:  Gary K Koski; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Anupama Sharma; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Brian J Czerniecki
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

6.  Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.

Authors:  Stacy E Thurber; Hung T Khong; Udai S Kammula; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 Jan-Feb       Impact factor: 4.456

7.  Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

Authors:  Douglas C Palmer; Sanjeeve Balasubramaniam; Ken-Ichi Hanada; Claudia Wrzesinski; Zhiya Yu; Shahram Farid; Marc R Theoret; Leroy N Hwang; Christopher A Klebanoff; Luca Gattinoni; Allan L Goldstein; James C Yang; Nicholas P Restifo
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

8.  Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers.

Authors:  Ke-Jun Nan; Yong-Chang Wei; Fu-Ling Zhou; Chun-Li Li; Chen-Guang Sui; Ling-Yun Hui; Cheng-Ge Gao
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

9.  Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.

Authors:  Angela Marzocchetti; Marco Lima; Troy Tompkins; Daniel G Kavanagh; Rajesh T Gandhi; David W O'Neill; Nina Bhardwaj; Igor J Koralnik
Journal:  Virology       Date:  2008-12-05       Impact factor: 3.616

10.  Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

Authors:  Kira Minkis; Daniel G Kavanagh; Galit Alter; Dusan Bogunovic; David O'Neill; Sylvia Adams; Anna Pavlick; Bruce D Walker; Mark A Brockman; Rajesh T Gandhi; Nina Bhardwaj
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.